Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Joshi A, Bhattacharjee A, Noronha V, Patil VM, Karpe A, Kadam N, Solanki L, Prabhash K. Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3-4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors. Indian J Cancer 2017;54:127-131. [PMID: 29199675 DOI: 10.4103/ijc.ijc_162_17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]

For:	Joshi A, Bhattacharjee A, Noronha V, Patil VM, Karpe A, Kadam N, Solanki L, Prabhash K. Development and validation of a predictive score, for identifying poor eastern cooperative oncology group performance status (performance status 3-4) advanced nonsmall cell lung cancer patients who are likely to benefit from tyrosine kinase inhibitors. Indian J Cancer 2017;54:127-131. [PMID: 29199675 DOI: 10.4103/ijc.ijc_162_17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]

Number

Cited by Other Article(s)

Yu S, Feng J. Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial". J Thorac Oncol 2024;19:173-174. [PMID: 38185511 DOI: 10.1016/j.jtho.2023.08.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 08/09/2023] [Indexed: 01/09/2024]